Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: An Italian perspective

Riccardo Asero, Giorgio W. Canonica, Antonio Cristaudo, Maria T. Fierro, Giampiero Girolomoni, Angelo V. Marzano, Eustachio Nettis, Patrizia Pepe, Paolo Pigatto, Oliviero Rossi

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Purpose of review The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. Recent findings Although modern second-generation H 1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H 1-antihistamines remains challenging. Summary Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.

Original languageEnglish
Pages (from-to)453-459
Number of pages7
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Urticaria
Histamine Antagonists
Therapeutics
Antibodies, Monoclonal, Humanized
Standard of Care
Disease Management
Omalizumab
Italy
Clinical Trials
Guidelines
Recurrence

Keywords

  • chronic spontaneous urticaria
  • omalizumab
  • second-generation H 1-antihistamines
  • treatment recommendations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab : An Italian perspective. / Asero, Riccardo; Canonica, Giorgio W.; Cristaudo, Antonio; Fierro, Maria T.; Girolomoni, Giampiero; Marzano, Angelo V.; Nettis, Eustachio; Pepe, Patrizia; Pigatto, Paolo; Rossi, Oliviero.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 17, No. 6, 01.12.2017, p. 453-459.

Research output: Contribution to journalReview article

@article{47d4b512b8c54d22bb99f5884691de8d,
title = "Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: An Italian perspective",
abstract = "Purpose of review The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. Recent findings Although modern second-generation H 1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H 1-antihistamines remains challenging. Summary Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.",
keywords = "chronic spontaneous urticaria, omalizumab, second-generation H 1-antihistamines, treatment recommendations",
author = "Riccardo Asero and Canonica, {Giorgio W.} and Antonio Cristaudo and Fierro, {Maria T.} and Giampiero Girolomoni and Marzano, {Angelo V.} and Eustachio Nettis and Patrizia Pepe and Paolo Pigatto and Oliviero Rossi",
year = "2017",
month = "12",
day = "1",
doi = "10.1097/ACI.0000000000000404",
language = "English",
volume = "17",
pages = "453--459",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab

T2 - An Italian perspective

AU - Asero, Riccardo

AU - Canonica, Giorgio W.

AU - Cristaudo, Antonio

AU - Fierro, Maria T.

AU - Girolomoni, Giampiero

AU - Marzano, Angelo V.

AU - Nettis, Eustachio

AU - Pepe, Patrizia

AU - Pigatto, Paolo

AU - Rossi, Oliviero

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose of review The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. Recent findings Although modern second-generation H 1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H 1-antihistamines remains challenging. Summary Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.

AB - Purpose of review The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. Recent findings Although modern second-generation H 1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H 1-antihistamines remains challenging. Summary Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.

KW - chronic spontaneous urticaria

KW - omalizumab

KW - second-generation H 1-antihistamines

KW - treatment recommendations

UR - http://www.scopus.com/inward/record.url?scp=85033780850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033780850&partnerID=8YFLogxK

U2 - 10.1097/ACI.0000000000000404

DO - 10.1097/ACI.0000000000000404

M3 - Review article

AN - SCOPUS:85033780850

VL - 17

SP - 453

EP - 459

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 6

ER -